There were several really good replies to the quoted post on $VKTX's Maintenance study. In particular there was a thread on the induction phase where @ResearchPulse1 and @GilaMonstrum commented that they rightly thought the WL originally projected at 19 wks was too aggressive especially given the titration scheme during induction is not known. Using a more conservative titration estimate @GilaMonstrum graciously created a new WL estimate at 19 wks using his much better model and that graph is included in this post requote. The "best guess" on the titration scheme is that it is 2.5mg, 5.0mg, 7.5mg, 10mg,15mg in 3week blocks which gets you to week 15 and then you have 4 weeks at the 17.5mg which is the final dose used in the Ph3 Vanquish study. A second "aggressive" guess at the titration scheme jumps goes 2.5, 5, 10, 15 in 3 wk blocks and ends at 17.5mg for 7 wks. (it is likely only one titration scheme will be used in induction to allow valid comparison of the different maintenance arms.) This gets a WL guess/estimate of around 16-17% which if achieved would be a great result at week 19 . We would also get new AE data on this large data set which would presumably be better that the good AE seen in ph2 as the titration scheme is likely less aggressive in this trial. Again this would be the longest trial data for VK2735 and with N around 180, the largest single arm where data is disclosed so it should help to predict ph3 Vanquish result. There are many other aspects of this trial that are very important. This is is a pioneering study that no one has done before because VK2735 is the only compound that can effectively support 4 different dosing regimens (SubQ weekly, and monthly plus Oral daily and weekly). There are several comments in the original post that cover the groundbreaking maintenance aspect of this study and if you are interested you can look at those aspects there. (and special thanks 🙏to @GilaMonstrum who always provides unique insights!)